Literature DB >> 18971119

Exogenous and endogenous hormones and breast cancer.

Wendy Y Chen1.   

Abstract

Exposure to higher levels of both exogenous and endogenous hormone is associated with breast cancer risk. Because of the association between breast cancer and HRT, only the minimal duration of HRT use is recommended for symptom control, and it is not recommended for chronic disease management. Current research issues include the role of progestins, other types of HRT, duration of unopposed estrogen use, and characteristics of cancers that develop on HRT. Circulating sex steroid levels are associated with breast cancer risk, but multiple issues need to be addressed before they are used routinely in clinical practice. Current research issues include measurement of levels for routine clinical practice, integration with standard breast cancer risk models and genetic polymorphism data, and applicability to estrogen-receptor-negative cancers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18971119      PMCID: PMC2599924          DOI: 10.1016/j.beem.2008.08.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  51 in total

1.  Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk.

Authors:  P A van den Brandt; D Spiegelman; S S Yaun; H O Adami; L Beeson; A R Folsom; G Fraser; R A Goldbohm; S Graham; L Kushi; J R Marshall; A B Miller; T Rohan; S A Smith-Warner; F E Speizer; W C Willett; A Wolk; D J Hunter
Journal:  Am J Epidemiol       Date:  2000-09-15       Impact factor: 4.897

2.  Bone mass and the risk of breast cancer among postmenopausal women.

Authors:  Y Zhang; D P Kiel; B E Kreger; L A Cupples; R C Ellison; J F Dorgan; A Schatzkin; D Levy; D T Felson
Journal:  N Engl J Med       Date:  1997-02-27       Impact factor: 91.245

3.  Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study.

Authors:  Rena Vassilopoulou-Sellin; Deborah S Cohen; Gabriel N Hortobagyi; Mary Jean Klein; Marsha McNeese; S Eva Singletary; Terry L Smith; Richard L Theriault
Journal:  Cancer       Date:  2002-11-01       Impact factor: 6.860

4.  Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants.

Authors:  M E Lippman; K A Krueger; S Eckert; A Sashegyi; E L Walls; S Jamal; J A Cauley; S R Cummings
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

5.  Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies.

Authors:  T Key; P Appleby; I Barnes; G Reeves
Journal:  J Natl Cancer Inst       Date:  2002-04-17       Impact factor: 13.506

6.  Serum estradiol level and risk of breast cancer during treatment with raloxifene.

Authors:  Steven R Cummings; Tu Duong; Emily Kenyon; Jane A Cauley; Malcolm Whitehead; Kathryn A Krueger
Journal:  JAMA       Date:  2002-01-09       Impact factor: 56.272

Review 7.  Overview of the main outcomes in breast-cancer prevention trials.

Authors:  J Cuzick; T Powles; U Veronesi; J Forbes; R Edwards; S Ashley; P Boyle
Journal:  Lancet       Date:  2003-01-25       Impact factor: 79.321

8.  Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.

Authors:  Lars Holmberg; Ole-Erik Iversen; Carl Magnus Rudenstam; Mats Hammar; Eero Kumpulainen; Janusz Jaskiewicz; Jacek Jassem; Daria Dobaczewska; Hans E Fjosne; Octavio Peralta; Rodrigo Arriagada; Marit Holmqvist; Johanna Maenpaa; Johanna Maenpa
Journal:  J Natl Cancer Inst       Date:  2008-03-25       Impact factor: 13.506

9.  Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period.

Authors:  S E Hankinson; J E Manson; D Spiegelman; W C Willett; C Longcope; F E Speizer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1995-09       Impact factor: 4.254

10.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

View more
  22 in total

1.  Redox cycling of catechol estrogens generating apurinic/apyrimidinic sites and 8-oxo-deoxyguanosine via reactive oxygen species differentiates equine and human estrogens.

Authors:  Zhican Wang; Esala R Chandrasena; Yang Yuan; Kuan-wei Peng; Richard B van Breemen; Gregory R J Thatcher; Judy L Bolton
Journal:  Chem Res Toxicol       Date:  2010-08-16       Impact factor: 3.739

2.  Complex organochlorine pesticide mixtures as determinant factor for breast cancer risk: a population-based case-control study in the Canary Islands (Spain).

Authors:  Luis D Boada; Manuel Zumbado; Luis Alberto Henríquez-Hernández; Maira Almeida-González; Eva E Alvarez-León; Lluis Serra-Majem; Octavio P Luzardo
Journal:  Environ Health       Date:  2012-04-25       Impact factor: 5.984

Review 3.  Changing concepts: Menopausal hormone therapy and breast cancer.

Authors:  Rowan T Chlebowski; Garnet L Anderson
Journal:  J Natl Cancer Inst       Date:  2012-03-16       Impact factor: 13.506

4.  A Comprehensive Model of Colorectal Cancer by Risk Factor Status and Subsite Using Data From the Nurses' Health Study.

Authors:  Esther K Wei; Graham A Colditz; Edward L Giovannucci; Kana Wu; Robert J Glynn; Charles S Fuchs; Meir Stampfer; Walter Willett; Shuji Ogino; Bernard Rosner
Journal:  Am J Epidemiol       Date:  2017-02-01       Impact factor: 4.897

5.  High-risk early breast cancer in patients under 40 years of age: Improved clinical outcome with total estrogen blockade and tailored chemotherapy.

Authors:  Francesco Recchia; Giampiero Candeloro; Stefania Discepoli; Marisa Grimaldi; Giovambattista Desideri; Stefano Necozione; Silvio Rea
Journal:  Exp Ther Med       Date:  2010-07-21       Impact factor: 2.447

6.  Effects of treadmill exercise training on liver fat accumulation and estrogen receptor alpha expression in intact and ovariectomized rats with or without estrogen replacement treatment.

Authors:  Like Hao; Yijing Wang; Yushuang Duan; Shumin Bu
Journal:  Eur J Appl Physiol       Date:  2010-03-16       Impact factor: 3.078

7.  Association between SHBG Asp327Asn (rs6259) polymorphism and breast cancer risk: a meta-analysis of 10,454 cases and 13,111 controls.

Authors:  Jue-Yu Zhou; Rong Shi; Hai-Lang Yu; Wen-Ling Zheng; Wen-Li Ma
Journal:  Mol Biol Rep       Date:  2012-06-19       Impact factor: 2.316

8.  White spotting variant mouse as an experimental model for ovarian aging and menopausal biology.

Authors:  Elizabeth R Smith; Toni Yeasky; Jain Qin Wei; Roberto A Miki; Kathy Q Cai; Jennifer L Smedberg; Wan-Lin Yang; Xiang-Xi Xu
Journal:  Menopause       Date:  2012-05       Impact factor: 2.953

Review 9.  Breast cancer and persistent organic pollutants (excluding DDT): a systematic literature review.

Authors:  Tafzila Akter Mouly; Leisa-Maree Leontjew Toms
Journal:  Environ Sci Pollut Res Int       Date:  2016-09-15       Impact factor: 4.223

Review 10.  Menopausal hormone therapy and cancer: changing clinical observations of target site specificity.

Authors:  Rowan T Chlebowski; Garnet L Anderson
Journal:  Steroids       Date:  2014-06-06       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.